Designer aminoglycosides that selectively inhibit cytoplasmic rather than mitochondrial ribosomes show decreased ototoxicity: a strategy for the treatment of genetic diseases.
about
Age-related hearing impairment and the triad of acquired hearing loss.XBP1 mitigates aminoglycoside-induced endoplasmic reticulum stress and neuronal cell death.Chemical-Induced Read-Through at Premature Termination Codons Determined by a Rapid Dual-Fluorescence System Based on S. cerevisiaeNovel small molecules potentiate premature termination codon readthrough by aminoglycosidesFoxO3a plays a key role in the protective effects of pomegranate peel extract against amikacin-induced ototoxicity.Structural basis for selective targeting of leishmanial ribosomes: aminoglycoside derivatives as promising therapeutics.Gentamicin differentially alters cellular metabolism of cochlear hair cells as revealed by NAD(P)H fluorescence lifetime imaging.Designer aminoglycosides prevent cochlear hair cell loss and hearing lossNew trends in aminoglycosides use.Identification and evaluation of improved 4'-O-(alkyl) 4,5-disubstituted 2-deoxystreptamines as next-generation aminoglycoside antibiotics.Singly modified amikacin and tobramycin derivatives show increased rRNA A-site binding and higher potency against resistant bacteria.Aminoglycoside Antibiotics: New Insights into the Biosynthetic Machinery of Old Drugs.Targeting mitochondrial function to protect against vision loss.Targeting Nonsense Mutations in Diseases with Translational Read-Through-Inducing Drugs (TRIDs).Protecting Mammalian Hair Cells from Aminoglycoside-Toxicity: Assessing Phenoxybenzamine's Potential.Rescue of the MERTK phagocytic defect in a human iPSC disease model using translational read-through inducing drugs.Crystal structure of eukaryotic ribosome and its complexes with inhibitors.Design of Novel Aminoglycoside Derivatives with Enhanced Suppression of Diseases-Causing Nonsense Mutations.N6', N6''', and O4' Modifications to Neomycin Affect Ribosomal Selectivity without Compromising Antibacterial Activity.When Proteins Start to Make Sense: Fine-tuning Aminoglycosides for PTC Suppression Therapy.Florfenicol-induced Mitochondrial Dysfunction Suppresses Cell Proliferation and Autophagy in Fibroblasts.Stressing out the ER in aminoglycoside-induced hearing loss.Towards the Prevention of Aminoglycoside-Related Hearing Loss.Pharmacogenetics of drug-induced ototoxicity caused by aminoglycosides and cisplatin.Structure-Activity Relationship Study of Leucyl-3-epi-deoxynegamycin for Potent Premature Termination Codon Readthrough.Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells.The effect of PTC124 on choroideremia fibroblasts and iPSC-derived RPE raises considerations for therapy.Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons.
P2860
Q26797403-8505E7CE-37D0-44F0-8A30-AF84312EE804Q27330304-C792C4B6-9B53-402B-9575-0BEFB4A51910Q28551611-BFDC767F-94C2-488E-88B0-537C5751B081Q28828711-C9D6817E-9ED4-48A5-AD08-929B2C3E6FD6Q30354162-9BCEBF3D-B92D-46D9-8975-5E40B74EB232Q30388445-9F0AF847-BF37-4413-AEEA-16A7C5005AC9Q30390875-45201616-D175-4938-92CB-3046DE645858Q30619790-745E9486-8D75-4C04-B3EC-507141CB1D82Q33951177-8FD0925D-2B42-4D0A-9B3D-1B9C70AA40F1Q34334742-663218D9-2AD5-4E50-9EAD-82D423F1E550Q34982853-486A33D5-90CD-4BF5-8D0D-5593276B8645Q38604106-0089F681-70F6-4817-B631-6DEC80E99871Q38694794-3F7F926E-DD2C-4AA6-BF37-234AD2E58A03Q38737126-882F807B-634E-4648-BB92-DF2D419D3331Q38786802-A1F53813-3958-4129-8215-F80C8E69414CQ38936740-E1E6E62B-1432-46A0-8ED4-CB01DE75DCF8Q39110276-F3E1D8BF-1A7E-43CA-834D-B36497AB844CQ40277213-C53F8754-2B60-48A4-926F-3E616D1FE18DQ40278411-EF2EF7B2-1297-4100-ACD6-5C3A5448D9B2Q42142778-722B5FA7-9EA2-4590-9A1F-839F93E21F05Q42659702-39422CC7-8BBE-41DE-A910-029067505CD3Q43143517-8AC867F1-4166-4878-9203-C21C22C48D73Q46270520-FE3748DC-E51E-45DD-9582-EA0EDF5994D2Q47819341-CD88CCFC-FB85-42A8-83D0-B636E005B29AQ50066093-7C453B12-61DA-4547-9065-9C2DBD291363Q51158606-18DF52B9-A782-4D16-8F86-6A719EEE8277Q55025407-167E687E-AE0A-46FE-9029-B093A8BE6814Q55497000-600E80DB-4FA4-4269-AA9E-E39A869446BF
P2860
Designer aminoglycosides that selectively inhibit cytoplasmic rather than mitochondrial ribosomes show decreased ototoxicity: a strategy for the treatment of genetic diseases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Designer aminoglycosides that ...... treatment of genetic diseases.
@en
Designer aminoglycosides that ...... treatment of genetic diseases.
@nl
type
label
Designer aminoglycosides that ...... treatment of genetic diseases.
@en
Designer aminoglycosides that ...... treatment of genetic diseases.
@nl
prefLabel
Designer aminoglycosides that ...... treatment of genetic diseases.
@en
Designer aminoglycosides that ...... treatment of genetic diseases.
@nl
P2093
P2860
P356
P1476
Designer aminoglycosides that ...... treatment of genetic diseases.
@en
P2093
Ann Kendall
Dorit Ben-Shachar
Eli Shulman
Esther G Meyron-Holtz
Jochen Schacht
Timor Baasov
Valery Belakhov
P2860
P304
P356
10.1074/JBC.M113.533588
P407
P577
2013-12-03T00:00:00Z